Addressing the Challenges of Alzheimer’s Agitation
Advancing IGC-AD1 in the CALMA trial—supporting patients and caregivers through science and compassion.
Our Science, Our Commitment
What is CALMA?
CALMA is a multicenter Phase 2 clinical trial designed to evaluate the safety and potential efficacy of IGC-AD1 for treating agitation in participants with dementia due to Alzheimer's disease.
Explore CALMA →What is IGC-AD1?
IGC-AD1 is IGC Pharma’s lead candidate—a partial CB1 receptor agonist with anti-inflammatory action, designed to address agitation associated with Alzheimer’s disease.
Learn About IGC‑AD1 →What is MINT-AD?
MINT-AD is IGC Pharma’s AI-powered platform that leverages multimodal data to support early Alzheimer’s detection and improve understanding of disease progression.
Discover MINT‑AD →Latest Press Releases
Explore how IGC Pharma’s data, trials, and milestones are shaping a brighter future for Alzheimer’s care.
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
IGC Pharma Leverages AI PlatformMINT-AD to Uncover Identify Socioeconomic Risk Factors Driving Alzheimer’s and Aging Trends
Together, we’re turning research into resilience, and innovation into care for millions worldwide.
0
Million
Americans projected to have Alzheimer’s disease by 2043
0
Million
Americans projected to have Alzheimer’s disease by 2060
0
th
Leading cause of death among Americans aged 65+
$
0
Trillion
Expected cost of Alzheimer’s and dementia by 2050 (in 2024 dollars) if no treatment or cure is found.
Pipeline
IGC Pharma’s pipeline bridges breakthroughs from AI-enhanced
early detection to IGC-AD1 and beyond, advancing Alzheimer’s
treatment frontiers.
In-depth insights,
real impact
“Science Spotlight” reveals our latest Alzheimer’s research, breakthroughs, and care innovations.
Resources
for Caregivers
This guide offers compassionate, evidence-based support for families caring for someone with Alzheimer’s disease. Written by leading neuropsychologists and enriched with real caregiver stories, it provides practical tips, emotional strategies, and step-by-step advice to understand the condition, manage daily challenges, and support emotional well-being. Supported by IGC Pharma, the book empowers caregivers with tips, strategies, and step-by-step guidance to improve care while also protecting their own well-being.
Investing in the Future:
IGC Pharma stands with families and vulnerable groups, investing in research, education, advocacy and Alzheimer’s awareness.
